Abstract
Background
Ductal carcinoma in situ (DCIS) is a neoplastic proliferation of epithelial cells which is confined within the basement membrane of the mammary ductal–lobular system. It is of interest to determine to what extent the potential to metastasize increases for DCIS patients when the basement membrane is breached (i.e. microinvasion is present).
Methods
We retrieved the records of 525,395 women who had either first primary DCIS or small (≤ 2.0 cm) node-negative invasive breast cancer in the Surveillance, Epidemiology and End Results (SEER) registries database (1990–2013). For each patient, we extracted information on year of diagnosis, age at diagnosis, tumour size, tumour grade, oestrogen receptor status, use of radiotherapy, type of surgery, cause of death and follow-up time. We classified patients into four groups, according to the size of the invasive component of the primary tumour. We estimated the actuarial rate of breast cancer-specific mortality at ten and 20 years for women in each size category.
Results
We identified 161,394 women with pure DCIS, 13,489 women with microinvasive carcinoma (≤ 0.1 cm of invasion), 153,856 women with invasive cancer 0.2–1.0 cm in size and 196,656 women with invasive cancer 1.1–2.0 cm in size. The 20-year actuarial breast cancer-specific mortality rate was 3.8% for women with pure DCIS, was 6.9% for women with microinvasive carcinoma, was 6.8% for women with invasive cancer 0.2–1.0 cm in size and was 12.1% for women with invasive cancer 1.1–2.0 cm in size. The adjusted hazard ratio for death associated with microinvasive carcinoma (vs. pure DCIS) was 2.00 (95% CI 1.76–2.26; p < 0.0001).
Conclusions
In terms of prognosis, microinvasive cancer more closely resembles small invasive cancer 0.2–1.0 cm) than pure DCIS. For invasive cancers under 1.0 cm, size has little impact on mortality.
References
Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ (eds) (2012) WHO classification of tumours of the breast. IARC, Lyon
Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) (2010) AJCC cancer staging manual, 7th edn. Springer, New York
Hoda SA, Chiu A, Prasad ML, Giri D, Hoda RS (2000) Are microinvasion and micrometastasis in breast cancer mountains or molehills? Am J Surg 180:305–308
Adamovich T, Simmons R (2003) Ductal carcinoma in situ with microinvasion. Am J Surg 186:112–116
Bianchi S, Vezzosi V (2008) Microinvasive carcinoma of the breast. Pathol Oncol Res 14:105–111
Shatat L, Gloyeske N, Madan R, O’Neil M, Tawfik O, Fan F (2013) Microinvasive breast carcinoma carries an excellent prognosis regardless of the tumor characteristics. Hum Pathol 44:2684–2689
Silver SA, Tavassoli FA (1998) Mammary ductal carcinoma in situ with microinvasion. Cancer 82:2382–2390
Schnitt SJ, Collins LC (eds) (2013) Microinvasive carcinoma: biopsy interpretation of the breast. Wolters Kluwer Lippincott Williams and Wilkins, Philadelphia, pp 267–280
Prasad ML, Osborne MP, Giri DD, Hoda SA (2000) Microinvasive carcinoma (T1mic) of the breast: clinicopathologic profile of 21 cases. Am J Surg Pathol 24:422–428
Padmore RF, Fowble B, Hoffman J, Rosser C, Hanlon A, Patchefsky AS (2000) Microinvasive breast carcinoma: clinicopathologic analysis of a single institution experience. Cancer 88:1403–1409
Margalit DN, Sreedhara M, Chen YH et al (2013) Microinvasive breast cancer: ER, PR, and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy. Ann Surg Oncol 20:811–818
Solin LJ, Fowble B, Yeh IT et al (1992) Microinvasive ductal carcinoma of the breast treated with breast-conserving surgery and definitive irradiation. Int J Radiat Oncol Biol Phys 23:961–968
Silverstein MJ, Waisman JR, Gamagami P et al (1990) Intraductal carcinoma of the breast (208 cases). Clinical factors influencing treatment choice. Cancer 66:102–108
Sue GR, Lannin DR, Killelea B, Chagpar AB (2013) Predictors of microinvasion and its prognostic role in ductal carcinoma in situ. Am J Surg 206:478–481
Ozkan-Gurdal S, Cabioglu N, Ozcinar B et al (2014) Factors predicting microinvasion in ductal carcinoma in situ. Asian Pac J Cancer Prev 15:55–60
Yu KD, Wu LM, Liu GY, Wu J, Di GH, Shen ZZ, Shao ZM (2011) Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component. Ann Surg Oncol 18:1342–1348
Mori M, Tsugawa K, Yamauchi H et al (2013) Pathological assessment of microinvasive carcinoma of the breast. Breast Cancer 20:331–335
Gradishar WJ, Anderson BO, Balassanian R et al (2015) Breast Cancer Version 2.2015. J Natl Compr Cancer Netw 13:448–475
Matsen CB, Hirsch A, Eaton A et al (2014) Extent of microinvasion in ductal carcinoma in situ is not associated with sentinel lymph node metastases. Ann Surg Oncol 21:3330–3335
Wang L, Zhang W, Lyu S et al (2015) Clinicopathologic characteristics and molecular subtypes of microinvasive carcinoma of the breast. Tumour Biol 36:2241–2248
Parikh RR, Haffty BG, Lannin D, Moran MS (2012) Ductal carcinoma in situ with microinvasion: prognostic implications, long-term outcomes, and role of axillary evaluation. Int J Radiat Oncol Biol Phys 82:7–13
de Mascarel I, MacGrogan G, Mathoulin-Pélissier S, Soubeyran I, Picot V, Coindre JM (2002) Breast ductal carcinoma in situ with microinvasion: a definition supported by a long-term study of 1248 serially sectioned ductal carcinomas. Cancer 94:2134–2142
Fang Y, Wu J, Wang W et al (2016) Biologic behavior and long-term outcomes of breast ductal carcinoma in situ with microinvasion. Oncotarget. https://doi.org/10.18632/oncotarget.11639
Niu HF, Wei LJ, Yu JP et al (2016) Is adjuvant chemotherapy necessary for patients with microinvasive breast cancer after surgery? Cancer Biol Med 13:142–149
Kwon JH, Kim YJ, Lee KW et al (2010) Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less. BMC Cancer 10:557
Wang W, Zhu W, Du F, Luo Y, Xu B (2017) The demographic features, clinicopathological characteristics and cancer-specific outcomes for patients with microinvasive breast cancer: A SEER database analysis. Sci Rep 7:42045
Virnig BA, Shamliyan T, Tuttle TM, Kane RL, Wilt TJ (2009) Diagnosis and management of ductal carcinoma in situ (DCIS). Evidence Report/Technology Assessment No. 185. AHRQ Publication No. 09-E018. Agency for Healthcare Research and Quality, Rockville
El Hage Chehade H, Headon H, Wazir U, Abtar H, Kasem A, Mokbel K (2017) Is sentinel lymph node biopsy indicated in patients with a diagnosis of ductal carcinoma in situ? A systematic literature review and meta-analysis. Am J Surg 213:171–180
Zetterlund L, Stemme S, Arnrup H, de Boniface J (2014) Incidence of and risk factors for sentinel lymph node metastasis in patients with a postoperative diagnosis of ductal carcinoma in situ. Br J Surg 101:488–494
Osako T, Iwase T, Kimura K, Horii R, Akiyama F (2013) Detection of occult invasion in ductal carcinoma in situ of the breast with sentinel node metastasis. Cancer Sci 104:453–457
Lakhani SR (1999) The transition from hyperplasia to invasive carcinoma of the breast. J Pathol 187:272–278
Yang M, Moriya T, Oguma M et al (2003) Microinvasive ductal carcinoma (T1mic) of the breast. The clinicopathological profile and immunohistochemical features of 28 cases. Pathol Int 53:422–428
Tulusan AH, Grünsteidel W, Ramming I, Egger H (1982) A contribution to the natural history of breast cancer. III. Changes in the basement membranes in breast cancers with stromal microinvasion. Arch Gynecol 231:209–218
Elling D, Vesper AS, Fiedler B, Martin H, Krocker J (2001) Intraductal component in invasive breast cancer: analysis of 250 resected surgical specimens. Breast 10:405–410
Cedolini C, Bertozzi S, Londero AP et al (2015) Impact of the presence and quantity of ductal carcinoma in situ component on the outcome of invasive breast cancer. Int J Clin Exp Pathol 8:13304–13313
Wong H, Lau S, Yau T, Cheung P, Epstein RJ (2010) Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer. Br J Cancer 102:1391–1396
Koscielny S, Tubiana M, Lê MG et al (1984) Br J Cancer 49:709–715
Tubiana M, Koscielny S (1999) The rationale for early diagnosis of cancer–the example of breast cancer. Acta Oncol 38:295–303
Pontén J (1990) Natural history of breast cancer. Acta Oncol 29:325–329
Karnofsky Hellman S, Lecture Memorial (1994) Natural history of small breast cancers. J Clin Oncol 12:2229–2234
Hanrahan EO, Gonzalez-Angulo AM, Giordano SH et al (2007) Overall survival and cause-specific mortality of patients with stage T1a, bN0M0 breast carcinoma. J Clin Oncol 25:4952–4960
Saadatmand S, Bretveld R, Siesling S, Tilanus-Linthorst MM (2015) Influence of tumour stage at breast cancer detection on survival in modern times: population based study in 173,797 patients. BMJ 351:h4901
Wo JY, Chen K, Neville BA, Lin NU, Punglia RS (2011) Effect of very small tumor size on cancer-specific mortality in node-positive breast cancer. J Clin Oncol 29:2619–2627
Foulkes WD, Reis-Filho JS, Narod SA (2010) Tumor size and survival in breast cancer–a reappraisal. Nat Rev Clin Oncol 7:348–353
Yu KD, Jiang YZ, Chen S, Cao ZG, Wu J, Shen ZZ, Shao ZM (2012) Effect of large tumor size on cancer-specific mortality in node-negative breast cancer. Mayo Clin Proc 87:1171–1180
Zheng YZ, Wang L, Hu X, Shao ZM (2015) Effect of tumor size on breast cancer-specific survival stratified by joint hormone receptor status in a SEER population-based study. Oncotarget 6:22985–22995
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Rights and permissions
About this article
Cite this article
Sopik, V., Sun, P. & Narod, S.A. Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ. Breast Cancer Res Treat 167, 787–795 (2018). https://doi.org/10.1007/s10549-017-4572-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-017-4572-2